Combination therapy with fibrates and ursodeoxycholic acid improves biochemical markers in primary biliary cholangitis patients across multiple studies

Photo by Olga DeLawrence / Unsplash

Frontiers in Medicine Published May 25, 2026 Medically reviewed May 25, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Combining fibrates with ursodeoxycholic acid significantly improves biochemical markers in primary biliary cholangitis, though survival data remain insufficient.

This comprehensive review analyzed data from multiple meta-analyses focusing on primary biliary cholangitis patients treated with ursodeoxycholic acid, either alone or combined with fibrates. The study included 3,276 unique patients after removing overlapping randomized controlled trials, providing a robust assessment of treatment efficacy and safety profiles across different therapeutic regimens.

results indicated that combination therapy yielded substantial improvements in key biochemical markers. Alkaline phosphatase levels decreased by a mean difference of minus 85.4 U/L, while bilirubin levels dropped by 0.45 mg/dL when fibrates were added to standard ursodeoxycholic acid treatment. These reductions were statistically significant and clinically meaningful for disease management.

Monotherapy with fibrates also demonstrated positive effects, reducing alkaline phosphatase by 48.7 U/L and bilirubin by 0.23 mg/dL. However, the combination approach consistently outperformed monotherapies in achieving biochemical response rates, with a relative risk of 1.42 favoring the dual-drug strategy over ursodeoxycholic acid alone.

Safety analysis revealed that adverse events occurred in 12% to 18% of cases, primarily involving mild pruritus and gastrointestinal symptoms. Serious adverse events were not reported, suggesting a favorable tolerability profile for both monotherapy and combination approaches in this patient population.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

BackgroundPrimary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive cholestasis. Although ursodeoxycholic acid (UDCA) is the standard therapy, a substantial proportion of patients show inadequate response, highlighting the need for alternative or adjunct treatments. Fibrates have emerged as adjunct agents to UDCA, but evidence remains inconsistent across trials and meta-analyses.MethodsWe conducted a systematic review of meta-analyses evaluating fibrates, alone or in combination with UDCA, in PBC patients. Databases were searched from inception to 2025. Primary outcomes included biochemical response (alkaline phosphatase [ALP] and bilirubin), treatment response rates, and adverse events. Overlap among meta-analyses was assessed using the corrected covered area (CCA), and methodological quality was evaluated with AMSTAR 2.ResultsTwenty-three meta-analyses were included, encompassing 45 unique randomized controlled trials (RCTs) with a total of 3,276 patients after removing duplicate RCTs across meta-analyses. Combination therapy of fibrates with UDCA significantly improved biochemical outcomes compared with UDCA alone (ALP: MD −85.4 U/L, 95% CI −102.7 to −68.1; bilirubin: MD −0.45 mg/dL, 95% CI −0.62 to −0.28). Biochemical response rates were higher with combination therapy (RR 1.42, 95% CI 1.25–1.61). Fibrate monotherapy showed moderate improvements in ALP (MD −48.7 U/L, 95% CI −67.5 to −29.9) and bilirubin (MD −0.23 mg/dL, 95% CI −0.39 to −0.07). Adverse events occurred in 12%–18%, mostly mild pruritus and gastrointestinal symptoms. Overlap between meta-analyses was high (CCA = 11%), and methodological quality ranged from moderate to high.ConclusionThis umbrella meta-analysis provides the most comprehensive synthesis to date, supporting UDCA–fibrate combination therapy for biochemical response in PBC. However, evidence on survival and transplant-free outcomes remains insufficient.